Compare ISPO & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ISPO | NNVC |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 26.7M |
| IPO Year | N/A | N/A |
| Metric | ISPO | NNVC |
|---|---|---|
| Price | $4.15 | $1.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 562.2K | 330.7K |
| Earning Date | 11-04-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $247,652,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $156.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.19 | $0.94 |
| 52 Week High | $7.17 | $2.23 |
| Indicator | ISPO | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 84.14 | 43.15 |
| Support Level | $4.14 | $1.20 |
| Resistance Level | $4.20 | $1.31 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 97.22 | 13.24 |
Inspirato Inc is a private, luxury hospitality club that provides its members with access to an exclusive portfolio of high-end vacation homes, luxury hotels, and curated travel experiences worldwide. The club offers personalized service, dedicated trip planning, and seamless access to exceptional properties through its innovative model designed to ensure the service, certainty and value that discerning customers demand. The Inspirato portfolio of curated luxury vacation options includes approximately 350 private luxury vacation homes and accommodations at over 220 luxury hotel and resort partners in over 180 destinations around the world.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.